CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Roncato, Rossana, Angelini, Jacopo, Pani, Arianna, Cecchin, Erika, Sartore-Bianchi, Andrea, Siena, Salvatore, De Mattia, Elena, Scaglione, Francesco, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504705/
https://www.ncbi.nlm.nih.gov/pubmed/32883002
http://dx.doi.org/10.3390/ijms21176350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504705/
https://www.ncbi.nlm.nih.gov/pubmed/32883002
http://dx.doi.org/10.3390/ijms21176350

Ejemplares similares